Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/2570/2019, ivr-215) ; a/darwin/9/2021 (h3n2) - like strain (a/darwin/9/2021, ivr-228); b/phuket/3073/2013 -like strain (b/phuket/3073/2013, wild type); b/austria/1359417/2021 - like strain (b/michigan/01/2021, wild type) - suspension for injection in pre-filled syringe - 15 microgram(s) - influenza vaccines; influenza, inactivated, split virus or surface antigen

Malta - English - Medicines Authority

viatris healthcare limited damastown industrial park, mulhuddart, dublin 15, dublin , ireland - suspension for injection in pre-filled syringe - influenza vaccine (split virion, inactivated) 15 µg - vaccines

Ireland - English - HPRA (Health Products Regulatory Authority)

viatris healthcare limited - a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/2570/2019, ivr-215) ; a/darwin/9/2021 (h3n2) - like strain (a/darwin/9/2021, ivr-228); b/phuket/3073/2013 -like strain (b/phuket/3073/2013, wild type); b/austria/1359417/2021 - like strain (b/michigan/01/2021, wild type) - suspension for injection in pre-filled syringe - influenza vaccines; influenza, inactivated, split virus or surface antigen

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - influenza virus a (h1n1) haemagglutinin 15ug (a/wisconsin/67/2022 (h1n1)pdm09-like virus (a/georgia/12/2022 (cvr-167))); influenza virus a (h3n2) haemagglutinin 15ug (a/massachusetts/18/2022 (h3n2)-like virus (a/sydney/1304/2022)); influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021-like virus (b/victoria lineage) (b/singapore/wuh4618/2021)); influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013-like virus (b/yamagata lineage) (b/singapore/inftt-16-0610/2016)) - suspension for injection - 60 mcg/0.5ml - active: influenza virus a (h1n1) haemagglutinin 15ug (a/wisconsin/67/2022 (h1n1)pdm09-like virus (a/georgia/12/2022 (cvr-167))) influenza virus a (h3n2) haemagglutinin 15ug (a/massachusetts/18/2022 (h3n2)-like virus (a/sydney/1304/2022)) influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021-like virus (b/victoria lineage) (b/singapore/wuh4618/2021)) influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013-like virus (b/yamagata lineage) (b/singapore/inftt-16-0610/2016)) excipient: dibasic sodium phosphate dihydrate magnesium chloride hexahydrate monobasic potassium phosphate potassium chloride sodium chloride water for injection - flucelvax quad is indicated for the prevention of influenza caused by influenza virus types a and b contained in the vaccine. the vaccine is indicated for use in individuals 6 months of age and above. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - influenza virus a (h1n1) haemagglutinin 7.5ug (a/victoria/4897/2022 (h1n1)pdm09-like virus (a/victoria/4897/2022 (ivr-238))); influenza virus a (h3n2) haemagglutinin 7.5ug (a/thailand/8/2022 (h3n2)-like virus (a/thailand/8/2022 (ivr-237))); influenza virus b (victoria) haemagglutinin 7.5ug (b/austria/1359417/2021(b/victoria lineage)-like virus (b/austria/1359417/2021 (bvr-26))); influenza virus b (yamagata) haemagglutinin 7.5ug (b/phuket/3073/2013-like virus (b/phuket/3073/2013 (bvr-1b))) - suspension for injection - 30 mcg/0.25ml - active: influenza virus a (h1n1) haemagglutinin 7.5ug (a/victoria/4897/2022 (h1n1)pdm09-like virus (a/victoria/4897/2022 (ivr-238))) influenza virus a (h3n2) haemagglutinin 7.5ug (a/thailand/8/2022 (h3n2)-like virus (a/thailand/8/2022 (ivr-237))) influenza virus b (victoria) haemagglutinin 7.5ug (b/austria/1359417/2021(b/victoria lineage)-like virus (b/austria/1359417/2021 (bvr-26))) influenza virus b (yamagata) haemagglutinin 7.5ug (b/phuket/3073/2013-like virus (b/phuket/3073/2013 (bvr-1b))) excipient: calcium chloride dihydrate dibasic sodium phosphate monobasic potassium phosphate monobasic sodium phosphate potassium chloride sodium chloride water for injection - for the prevention of influenza caused by influenza virus, types a and b contained in the vaccine. afluria quad junior vaccine is indicated for use in children aged 6 months to 35 months inclusive. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - influenza virus a (h1n1) haemagglutinin 15ug (a/victoria/4897/2022 (h1n1)pdm09-like virus (a/victoria/4897/2022 (ivr-238))); influenza virus a (h3n2) haemagglutinin 15ug (a/thailand/8/2022 (h3n2)-like virus (a/thailand/8/2022 (ivr-237))); influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021(b/victoria lineage)-like virus (b/austria/1359417/2021 (bvr-26))); influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013-like virus (b/phuket/3073/2013 bvr-1b)) - suspension for injection - 60 mcg/0.5ml - active: influenza virus a (h1n1) haemagglutinin 15ug (a/victoria/4897/2022 (h1n1)pdm09-like virus (a/victoria/4897/2022 (ivr-238))) influenza virus a (h3n2) haemagglutinin 15ug (a/thailand/8/2022 (h3n2)-like virus (a/thailand/8/2022 (ivr-237))) influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021(b/victoria lineage)-like virus (b/austria/1359417/2021 (bvr-26))) influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013-like virus (b/phuket/3073/2013 bvr-1b)) excipient: calcium chloride dihydrate citric acid monohydrate dibasic sodium phosphate dihydrate magnesium chloride hexahydrate monobasic potassium phosphate polysorbate 80 potassium chloride sodium chloride sodium citrate dihydrate sorbitan trioleate squalene water for injection - active immunisation against influenza in persons 65 years of age and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - varicella-zoster virus, oka/merck strain, live, attenuated 19400 pfu;   - injection with diluent - 19400 pfu - active: varicella-zoster virus, oka/merck strain, live, attenuated 19400 pfu   excipient: dibasic sodium phosphate monohydrate gelatin monobasic potassium phosphate monosodium glutamate potassium chloride sodium chloride sucrose urea water for injection - zostavax is indicated for: · prevention of herpes zoster (shingles)

Canada - English - Health Canada

glaxosmithkline inc - varicella-zoster virus glycoprotein e antigen - suspension - 50mcg - varicella-zoster virus glycoprotein e antigen 50mcg - vaccines

Canada - English - Health Canada

sanofi pasteur limited - recombinant haemagglutinin protein-strain a (h1n1); recombinant haemagglutinin protein-strain a (h3n2); recombinant haemagglutinin protein-strain b (victoria); recombinant haemagglutinin protein-strain b (yamagata) - solution - 45mcg; 45mcg; 45mcg; 45mcg - recombinant haemagglutinin protein-strain a (h1n1) 45mcg; recombinant haemagglutinin protein-strain a (h3n2) 45mcg; recombinant haemagglutinin protein-strain b (victoria) 45mcg; recombinant haemagglutinin protein-strain b (yamagata) 45mcg - vaccines

European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - respiratory syncytial virus infections - vaccines - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. see sections 4.2 and 5.1.active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv.the use of this vaccine should be in accordance with official recommendations.